Literature DB >> 33300186

Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma.

Joanne E Kavanagh1,2, Andrew P Hearn1,2, Grainne d'Ancona1, Jaideep Dhariwal1, Cris Roxas1, Linda Green1, Louise Thomson1, Mariana Fernandes1, Brian D Kent3,4, Alexandra M Nanzer1, David J Jackson1,2.   

Abstract

Entities:  

Year:  2020        PMID： 33300186     DOI： 10.1111/all.14693

Source DB:  PubMed          Journal:  Allergy        ISSN： 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  6 in total

1.  Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma.

Authors:  Ana Gómez-Bastero Fernández; Juan Francisco Medina Gallardo; Julio Delgado Romero; Auxiliadora Romero Falcón; Cristina Benito Bernáldez; Javier Gallego Borrego; Francisco Javier Álvarez-Gutiérrez
Journal:  J Asthma Allergy       Date:  2022-05-25

2.  Anti-interleukin 5 therapies failure criteria in severe asthma: a Delphi-consensus study.

Authors:  Laura Mattei; Carey M Suehs; Khuder Alagha; Arnaud Bourdin; Christophe Brousse; Jeremy Charriot; Gilles Devouassoux; Stephanie Fry; Laurent Guilleminault; Marion Gouitaa; Camille Taille; Pascal Chanez; Laurie Pahus
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

3.  Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment.

Authors:  Adel H Mansur
Journal:  Respir Med Case Rep       Date:  2021-11-27

Review 4.  A pragmatic guide to choosing biologic therapies in severe asthma.

Authors:  Joanne E Kavanagh; Andrew P Hearn; David J Jackson
Journal:  Breathe (Sheff)       Date:  2021-12

5.  Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis.

Authors:  Cristiano Caruso; Paolo Cameli; Elena Altieri; Maria Aliani; Pietro Bracciale; Luisa Brussino; Maria Filomena Caiaffa; Giorgio Walter Canonica; Stefano Centanni; Maria D'Amato; Stefano Del Giacco; Fausto De Michele; Elide Anna Pastorello; Girolamo Pelaia; Paola Rogliani; Micaela Romagnoli; Pietro Schino; Marco Caminati; Alessandra Vultaggio; Alessandro Zullo; Sara Rizzoli; Silvia Boarino; Gianfranco Vitiello; Francesco Menzella; Fabiano Di Marco
Journal:  Front Med (Lausanne)       Date:  2022-09-02

6.  Effect of CRTH2 antagonism on the response to experimental rhinovirus infection in asthma: a pilot randomised controlled trial.

Authors:  Hugo Farne; Nicholas Glanville; Nicholas Johnson; Tata Kebadze; Julia Aniscenko; Eteri Regis; Jie Zhu; Maria-Belen Trujillo-Torralbo; Onn Min Kon; Patrick Mallia; A Toby Prevost; Michael R Edwards; Sebastian L Johnston; Aran Singanayagam; David J Jackson
Journal:  Thorax       Date:  2021-10-29       Impact factor: 9.102
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.